October 29, 2021 -- BridgeBio Pharma announced it is collaborating with Columbia University and Mount Sinai Health System to develop potential therapies to treat individuals with genetic diseases and cancers.
The company has initiated 25 collaborations with leading institutions around the world that are focused on providing therapeutic options to patients with unmet needs.
BridgeBio noted Columbia University and Mount Sinai's respective expertise in developing breakthroughs for patients with genetic diseases and genetically driven cancers.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
